Development of in vitro models to demonstrate the ability of PecSys®, an in situ nasal gelling technology, to reduce nasal run-off and drip

References

• Behl CR, Pimplaskar HK, Sileno J, deMeireles J, Romeo VD. (1998). Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Delivery Rev, 29:89–116.
   PubMed Web of Science ®Google Scholar
• Watts P, Smith A. (2009). PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opin Drug Deliv, 6:543–552.
   PubMed Web of Science ®Google Scholar
• May, CD. (1990). Industrial pectins: Sources, production and applications. Carbohydrate Polymers, 12:79–99.
   Web of Science ®Google Scholar
• Rolin C. (1993). Pectin. In: Whistler RL, BeMiller JN, eds. Industrial Gums. New York: Academic Press, 257–293.
   Google Scholar
• Grant GT, Morris ER, Rees DA, Smith PJC, Thom D. (1973). Biological interactions between polysaccharides and divalent cations: The egg-box model. FEBS Letters, 32:195–198.
   Web of Science ®Google Scholar
• Fisher A, Watling M, Smith A, Knight A. (2010). Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther, 48:138–145.
   PubMed Web of Science ®Google Scholar
• Fisher A, Watling M, Smith A, Knight A. (2010). Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800 µg in healthy volunteers. Int J Clin Pharmacol Ther, 48:860–867.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Stahlman JE, Leflein J, Meltzer S, Lim J, Dalal AA et al. (2008). Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: a randomized, multicenter, double-blind, single-dose, crossover study. Clin Ther, 30:271–279.
   PubMed Web of Science ®Google Scholar
• Mahadevia P, Shah S, Mannix S, Brewster-Jordan J, Kleinman L, Liebman C et al. (2006). Willingness to pay for sensory attributes of intranasal corticosteroids among patients with allergic rhinitis. J Manag Care Pharm, 12:143–151.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Raffaeli W, Torres LM, Sitte T, Deka AC, Herrera IG et al.; Fentanyl Nasal Spray Study 045 Investigators Group. (2010). Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients. J Opioid Manag, 6:319–328.
   PubMedGoogle Scholar
• Taylor D, Galan V, Weinstein SM, Reyes E, Pupo-Araya AR, Rauck R; Fentanyl Pectin Nasal Spray 043 Study Group. (2010). Fentanyl pectin nasal spray in breakthrough cancer pain. J Support Oncol, 8:184–190.
   PubMedGoogle Scholar
• Portenoy RK, Burton AW, Gabrail N, Taylor D; Fentanyl Pectin Nasal Spray 043 Study Group. (2010). A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain, 151:617–624.
   PubMed Web of Science ®Google Scholar
• Davies A, Sitte T, Elsner F, Reale C, Espinosa J, Brooks D et al. (2011). Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage, 41:358–366.
   PubMed Web of Science ®Google Scholar
• Harikarnpakdee S, Lipipun V, Sutanthavibul N, Ritthidej GC. (2006). Spray-dried mucoadhesive microspheres: preparation and transport through nasal cell monolayer. AAPS PharmSciTech, 7:E12.
   PubMed Web of Science ®Google Scholar
• Kieweg SL, Geonnotti AR, Katz DF. (2004). Gravity-induced coating flows of vaginal gel formulations: in vitro experimental analysis. J Pharm Sci, 93:2941–2952.
   PubMed Web of Science ®Google Scholar
• Kockisch S, Rees GD, Young SA, Tsibouklis J, Smart JD. (2003). Polymeric microspheres for drug delivery to the oral cavity: an in vitro evaluation of mucoadhesive potential. J Pharm Sci, 92:1614–1623.
   PubMed Web of Science ®Google Scholar
• Eichner H, Behbehani AA, Hochstrasser K. (1983). [Diagnostic value of nasal secretions, current state: normal values. 1]. Laryngol Rhinol Otol (Stuttg), 62:561–565.
   PubMedGoogle Scholar
• Mahajan HS, Gattani SG. (2009). Gellan gum based microparticles of metoclopromide hydrochloride for intranasal delivery: development and evaluation. Chem Pharm Bull, 57:388–392.
   PubMed Web of Science ®Google Scholar
• Kundoor V, Dalby RN. (2010). Assessment of nasal spray deposition pattern in a silicone human nose model using a color-based method. Pharm Res, 27:30–36.
   PubMed Web of Science ®Google Scholar
• Kundoor V, Dalby RN. (2011). Effect of formulation- and administration-related variables on deposition pattern of nasal spray pumps evaluated using a nasal cast. Pharm Res, 28:1895–1904.
   PubMed Web of Science ®Google Scholar
• Grape S, Schug SA, Lauer S, Schug BS. (2010). Formulations of fentanyl for the management of pain. Drugs, 70:57–72.
   PubMed Web of Science ®Google Scholar
• Fine PG. (1999). Clinical experience with Actiq® (oral transmucosal fentanyl citrate) for the treatment of cancer pain. Today’s Therapeutic Trends, 17:1–11.
   Google Scholar
• Mystakidou K, Tsilika E, Tsiatas M, Vlahos L. (2007). Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology. Int J Nanomedicine, 2:49–54.
   PubMed Web of Science ®Google Scholar
• Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. (2006). A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res, 23:2709–2728.
   PubMed Web of Science ®Google Scholar
• Perez AP, Mundiña-Weilenmann C, Romero EL, Morilla MJ. (2012). Increased brain radioactivity by intranasal P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels. Int J Nanomedicine, 7:1373–1385.
   PubMed Web of Science ®Google Scholar
• Basu S, Bandyopadhyay AK. (2010). Development and characterization of mucoadhesive in situ nasal gel of midazolam prepared with Ficus carica mucilage. AAPS PharmSciTech, 11:1223–1231.
   PubMed Web of Science ®Google Scholar
• Majithiya RJ, Ghosh PK, Umrethia ML, Murthy RS. (2006). Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan. AAPS PharmSciTech, 7:67.
   PubMed Web of Science ®Google Scholar
• Cao SL, Zhang QZ, Jiang XG. (2007). Preparation of ion-activated in situ gel systems of scopolamine hydrobromide and evaluation of its antimotion sickness efficacy. Acta Pharmacol Sin, 28:584–590.
   PubMed Web of Science ®Google Scholar
• Cao SL, Ren XW, Zhang QZ, Chen E, Xu F, Chen J et al. (2009). In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate. Int J Pharm, 365:109–115.
   PubMed Web of Science ®Google Scholar
• Cai Z, Song X, Sun F, Yang Z, Hou S, Liu Z. (2011). Formulation and evaluation of in situ gelling systems for intranasal administration of gastrodin. AAPS PharmSciTech, 12:1102–1109.
   PubMed Web of Science ®Google Scholar
• Harish NM, Prabhu P, Charyulu RN, Gulzar MA, Subrahmanyam EV. (2009). Formulation and Evaluation of in situ Gels Containing Clotrimazole for Oral Candidiasis. Indian J Pharm Sci, 71:421–427.
   PubMed Web of Science ®Google Scholar
• Narayana RC, Harish NM, Gulzar A M, Prabhakara P, Singh AK, Subrahmanyam EV. (2009). Formulation and in vitro evaluation of in situ gels containing secnidazole for vaginitis. Yakugaku Zasshi, 129:569–574.
   PubMed Web of Science ®Google Scholar
• Gurny R, Boye T, Ibrahim H. (1985). Ocular therapy with nanoparticulate systems for controlled drug delivery. J Contr Release, 2:353–361.
   Google Scholar
• Guo Y, Laube B, Dalby R. (2005). The effect of formulation variables and breathing patterns on the site of nasal deposition in an anatomically correct model. Pharm Res, 22:1871–1878.
   PubMed Web of Science ®Google Scholar